| A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations C Norman, S Halter, B Haschimi, D Acreman, J Smith, AJ Krotulski, ... Drug Testing and Analysis 13 (4), 841-852, 2021 | 33 | 2021 |
| Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services PE Oomen, D Schori, K Tögel-Lins, D Acreman, S Chenorhokian, A Luf, ... International Journal of Drug Policy 100, 103493, 2022 | 32 | 2022 |
| Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use C Woodward, J Smith, D Acreman, N Kumar Annals of Hepato-biliary-pancreatic Surgery 23 (2), 174, 2019 | 16 | 2019 |
| Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs VD Hope, J McVeigh, E Begley, R Glass, C Edmundson, E Heinsbroek, ... Drug and Alcohol Review 40 (4), 586-596, 2021 | 10 | 2021 |
| Facilitators and barriers to health care access amongst people using image and performance enhancing drugs in Wales: Findings & Outcomes Report. V Hope, C Leavey, G Morgan, D Acreman, D Turner, J Smith Public Health Wales, 2020 | 9 | 2020 |
| Size matters: comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012–2021 RQ Vrolijk, F Measham, A Quesada, A Luf, D Schori, S Radley, ... Drugs, Habits and Social Policy 23 (3), 207-219, 2022 | 4 | 2022 |
| Image and Performance Enhancing Drugs J Campbell, C Tanner, J Kean, G Morgan, D Acreman, J Smith | 1 | 2017 |
| Oral Communications D Acreman, M Gagol, A Hutchings, A Westwell, M Lyons, J Smith, ... Annali di Stomatologia 2, 0-0, 2013 | | 2013 |
